凌科药业（杭州）有限公司 Lingke Pharmaceutical
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001 2024-03-22 08:00
Lynk Pharmaceuticals Announced First Rheumatoid Arthritis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001 2023-12-20 08:00
Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB 2023-09-21 08:00
Lynk Pharmaceuticals Announces Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Ankylosing Spondylitis 2023-08-23 08:00
Lynk Pharmaceuticals Announced Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Atopic Dermatitis 2023-08-09 08:00
Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed with LNK01004 in Phase Ib Clinical Study 2023-07-21 08:00
Lynk Pharmaceuticals Completes 200 Million RMB Series C1 Financing to Accelerate Clinical Development of Core Products 2023-05-31 08:25
Lynk Pharmaceuticals Announces First Cohort of Psoriatic Patients Dosed with LNK01004 in Phase Ib Clinical Study 2023-05-25 08:00
LYNK's LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis 2023-05-16 08:00
Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects 2023-04-04 20:00
Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects 2023-04-04 08:00
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis 2022-12-05 08:00
Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China 2022-08-03 08:00
Lynk Pharmaceuticals Announces the First Participant Dosed in Phase I Trial of LNK01004 2022-07-29 10:00
Lynk Pharmaceuticals Announces Clinical Approval in China for Its Class I New Drug LNK01004 2022-04-22 08:00
Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001 2022-03-18 13:28
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis 2022-02-28 08:00
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis 2022-01-19 08:00
Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001 2021-12-01 08:00
Lynk Pharmaceuticals announced the completion of Series B financing of $50 million 2021-08-27 08:00
1 2